Artificial Intelligence in Assistive Technology

By Michael Awood

October 1, 2023

Artificial Intelligence (AI) has been a game-changer in many sectors, including healthcare. AI has been successful in Assistive Technology, an area that’s always been at the forefront of technology.

AI has the potential to revolutionize AT, as highlighted by the UN Special Rapporteur on the rights of persons with disabilities. It can enhance assistive robots, autonomous wheelchairs, and guidance systems for visually impaired individuals. Speech recognition improvements are improving AT applications, while smart homes can boost independence and well-being.

However, challenges exist. AI systems learn from data “training sets,” and if these sets lack diversity, the technology may not reflect the needs of diverse human experiences. Also, the transparency of the data labelling process and lack of diversity in data collection can lead to biased AI tools. Therefore, AI training sets must include AT users to ensure the technology caters to their needs.

Many of these technologies are still in development and have yet to overcome significant barriers. For example, people with dysarthria are hard for speech recognition systems to understand, and smart wheelchairs have trouble detecting descending stairs.

The healthcare workforce should be trained in using digital products and AI tools to educate future generations. This is part of a broader framework to support these technologies’ development and sustainability.

Regulations, standards, and policies also need to keep pace with technological advancements. The proposed EU legislation has raised concerns among the European Disability Forum as it does not sufficiently address and protect the rights of persons with disabilities, especially when AI is used for access to public and private services.

AI could revolutionize AT, but it’s important to involve AT users and healthcare providers in the development process. This involves talking about the ethical use of these technologies and creating rules and policies to govern them.

Reference url

Recent Posts

Donanemab Alzheimer’s Approval: A New Era in Treatment

By João L. Carapinha

August 8, 2025

The EMA granted marketing authorization for donanemab, a monoclonal antibody targeting beta-amyloid plaques. It treats early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia with confirmed amyloid pathology). This approval highlights donanemab's role in Alzheimer's trea...
Building a Better Ecosystem for Digitally Enabled Diabetes Care in Europe
Digitally enabled diabetes care is rapidly transforming the management of Type 2 diabetes (T2D) across Europe. How does expanding access to these digital solutions improve health outcomes and reduce costs for individuals and health systems? Early evidence and recent policy recommendations (publis...
AI in Real-World Evidence: Insights from Mitch Higashi

By Staff Writer

August 7, 2025

In this update, we review the Q&A with Mitch Higashi, PhD, ISPOR’s Associate Chief Science Officer published on Pharmalive. It discusses AI in Real-World Evidence (RWE) and health technology assessments (HTA). Key themes include AI-driven early disease detection and NLP tackling unstructured ...